Recipharm and Medspray have completed a joint venture, establishing Resyca.
The company will develop and exploit softmist spray nozzle technology for pharmaceutical applications. It aims to eliminate the need for propellants by delivering therapies deep into the lungs with lower doses, as less ends up in the mouth and throat.
Jean-François Hilaire, EVP Strategy and Global Integration at Recipharm, said: “We are seeing some excellent traction in this field and have already signed an agreement with several more in the pipeline. The fit with Recipharm’s broader inhalation activities is making our work with Medspray very closely aligned with our strategy as we work to become the world leading integrated device development and manufacturing provider”.
Han van Egmond, CEO of Medspray, said: “Our partnership with Recipharm cements the exciting opportunities we see for the softmist spray nozzle technology in pharmaceutical applications. The potential advantages to both patient and environment make a highly compelling case for its adoption”.
Resyca will operate development facilities in Munich, Germany and spray nozzles will be supplied exclusively from Medspray in the Netherlands. It’s planned that commercial supply of finished devices will be manufactured and supplied by other Recipharm affiliates including the specialist device manufacturing capabilities located in King’s Lynn, UK.
Recipharm will receive an exclusive license to offer its customers the development and manufacturing of syringe-based devices using the softmist nozzle technology. Such devices will be marketed under the brand Bespak by Recipharm.
